Funding for this research was provided by:
National Institute on Aging (R03AG063255, RF1AG054156)
U.S. Department of Veterans Affairs (I01-CX001038)
H2020 European Research Council ((#681712)
Swedish Research Council (#2017-00915, #2018-02532)
Received: 15 June 2020
Accepted: 1 September 2020
First Online: 17 September 2020
Ethics approval and consent to participate
: Approval and oversight for the study protocol were provided by the BUMC Institutional Review Board and was in accordance with the ethical standards of the Committee on Human Experimentation of our institution and the Declaration of Helsinki.
: Not applicable
: Henrik Zetterberg (HZ) has served at the scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, and CogRx; has given lectures in symposia sponsored by Fujirebio, Alzecure, and Biogen; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. Kaj Blennow has served as a consultant at the advisory boards or at the data monitoring committees for Abcam, Axon, Biogen, Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. The other authors have no conflict of interest to report.